Rubio-Viqueira, BelenTarruella, Margarita MajemLazaro, MartinEstevez, Sergio VazquezCordoba-Ortega, Juan FelipeMaiques, Inmaculada MaestuGonzalez, Jorge GarciaCordellat, Ana BlascoValdivia-Bautista, JavierArenas, Carmen GonzalezSanchez Torres, Jose Miguel2025-01-072025-01-072021-11-261758-1966https://hdl.handle.net/10668/26310Aim: To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain. Methods: Multicenter, retrospective study. Results: Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1. Conclusion: PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/advancedfirst-line treatmentimmunotherapymetastaticNSCLCPD-L1 expressionOpen-labelPembrolizumabChemotherapyMulticenterTherapyPhase-3research article34899993open access10.2217/lmt-2021-00081758-1974https://doi.org/10.2217/lmt-2021-0008722706800001